Molecular Oncologic Imaging en-US (Prof. Dr. Zehra Pınar Koç) (Prof. Dr. Zehra Pınar Koç) Mon, 01 Aug 2022 16:33:20 +0000 OJS 60 Abdominal Vasculitis Determined by Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography <table width="100%"> <tbody> <tr> <td width="72%"> <p>Aim: The retrospective evaluation of abdominal vasculitis detected by FDG PET/CT examinations.</p> <p>Materials and Methods: Seven patients (4 Female, 4 Male, 26-72 years old) were subjects of this study. The images of the patients as well as clinic and pathologic features were analyzed retrospectively.</p> <p>Results: The determination of the abdominal vasculitis is possible as primary diagnosis or incidentally during an investigation of a known another disease (malignancy).</p> <p>Conclusion: This case series demonstrates the significance of this clinical entity as well as associated malignancy with this disease by FDG PET/CT.</p> </td> </tr> </tbody> </table> Zehra Pınar Koc, Pınar Pelin Özcan, Nurdan Oruçoğlu, Hamide Sayar Copyright (c) 2022 Molecular Oncologic Imaging Sun, 31 Jul 2022 00:00:00 +0000 Coincident Pelvic Uptake in the F-18 FDG PET/CT Imaging in Patients With the Diagnosis of Breast Carcinoma <table width="100%"> <tbody> <tr> <td width="72%"> <p>Objective: The F-18 FDG PET/CT imaging is a commonly preferred imaging modality for staging of breast carcinoma. The gynecological tumors are more frequently present in patients with breast carcinoma compared to the general population. The aim of this study was to investigate the clinical importance of the uterine and adnexal uptake observed incidentally in the F-18 FDG PET/CT imaging of breast carcinoma.</p> <p>Patients and Methods: The F-18 FDG PET/CT images (performed for staging or treatment response evaluation purposes) of the patients (sixty six women mean: 49,5 (12,6 years old) with diagnosis of the breast carcinoma with suspicious uterine and/or adnexal uptake were included in the study. The imaging results were compared with pelvic examination data as well as operative and pathology results.</p> <p>Results: In the imaging studies the increased FDG uptake sites were the primary tumor (mean 27, 3 (24,5) mm, SUVmax=31,3 (20) in 35 patients, and in 22 patients additional axillar metastases and distant metastasis in 19 patient were observed. Among the patients involved in the study 29 had unilateral adnexal uptake and/or lesion and/or uterine uptake and others had suspicious findings without increased uptake.</p> <p><em>Conclusion: Referral of the patients for gynecological examination with coincident uterine and adnexal abnormal uptake in the F-18 FDG PET/CT would be the appropriate approach in the patients with the diagnosis of breast cancer</em></p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> </td> </tr> </tbody> </table> Zehra Pınar Koc, Pınar Pelin Özcan, Emel Sezer, Ahmet Dağ, Ferah Tuncel, Tolgay Tuyan İlhan Copyright (c) 2022 Molecular Oncologic Imaging Sun, 31 Jul 2022 00:00:00 +0000 Metastatic Brain Lesions of Colon Carcinoma on F-18 Fluorodeoxyglucose (FDG) Positron Emission Tomography/Computed Tomography (PET/CT) <p class="zetMetin" style="text-indent: 0cm;">Metastatic brain tumors of the colon carcinoma usually presents with multiorgan metastasis and associated with worse prognosis. The diagnostic imaging modality of brain metastasis is MR thus there are limited data about FDG PET/CT appearance of these tumors. This is the report of three cases with pathological diagnosis of brain metastasis of colon metastasis with FDG PET/CT images.</p> Zehra Pınar Koc, Pınar Pelin Özcan, Hamide Sayar Copyright (c) 2022 Molecular Oncologic Imaging Sun, 31 Jul 2022 00:00:00 +0000 Ga-68 PSMA PET-CT in Initial Staging First Line Imaging of Prostate Cancer: The Clinical Impact of Oligometastatic Disease <p>Background: Imaging plays an important role in the evaluation of prostate cancer patients. In recent years, much attention has been focused on 68Ga-PSMA PET-CT in prostate cancer patients and has been widely used for staging, especially biochemical relapse-restaging and therapy response for these patients. The aim of this study was evaluate 68 Ga PSMA PET-CT imaging in initial staging-first line imaging of prostate cancer from low to high risk patients.</p> <p>Materials &amp; Metods: Patients with low, intermediate and high risk newly diagnosed prostate cancer referred for initial staging of prostate cancer were included in the study. Histopathology and follow-up clinical and radiological information after PET/CT scanning served as the standard of reference.</p> <p>Results: The study included a total of 176 consecutive patients underwent 68 Ga PSMA PET-CT for initial staging with prostate cancer final histopathology result. There were a total of 27 low risk, 35 intermediate risk and 114 high risk patients included in the study. SUVmax in the primary tumor was correlated significantly with PSA levels and patient risk group. Mean SUVmax value of the primary prostate lesion were 16.6 %, 25.8 % and 35.2 % in low, intermediate and high risk patients, respectively. Oligometastases were detected in low and intermediate groups in similar proportions and slightly less in high risk patients&nbsp; (22 %, 22.8 % and 15.7 % in low, intermediate and high risk patients respectively), whereas multipl metastases were detected significantly higher in high risk group patients (3.7 %, 8.6 % and 52.6 %, in low, intermediate and high risk patients respectively.</p> <p>Conclusions: Oligometastases was detected with a relative high rate in low and intermediate risk group patients. Ga-68 PSMA PET-CT imaging in newly diagnosed prostate cancer patients even in low risk patients was found to be quite useful in the current study. Ga-68 PSMA imaging should be done in all risk groups as a first-line imaging modality. This finding should be supported by other studies with large number of patients.</p> Pınar Pelin Özcan, Zehra Pınar Koç, Vehbi Erçolak, Zeynep Selcan Sağlam, Gökçe Yavan, Murat Bozlu, Mesut Tek, Erdem Akbay Copyright (c) 2022 Molecular Oncologic Imaging Sun, 31 Jul 2022 00:00:00 +0000 Abdominal Mass shown by the FDG PET/CT with diagnosis of Burkitt Lymphoma <table width="100%"> <tbody> <tr> <td width="72%"> <p>Positron emission tomography/computed tomography (PET/CT) with&nbsp;<sup>18</sup>F-fluorodeoxyglucose (<sup>18</sup>F-FDG) is currently a standard imaging examination used in clinical practice, and plays an essential role in preoperative systemic evaluation and tumor staging in various cancer patients. With this method, it is possible to measure or compare metabolic changes in cancer cells. With combined PET/CT, it is possible to determine the correct anatomical location in hypermetabolic tumors uptake of FDG. In this review, we presented the use of FDG-PET in three different malignancies.</p> </td> </tr> </tbody> </table> Gökçe Yavan, Zehra Pınar Koç, Pınar Pelin Özcan Copyright (c) 2022 Molecular Oncologic Imaging Sun, 31 Jul 2022 00:00:00 +0000